December 5, 2017

WorkCompRecap: Cannabinoids & Compliance!

Today’s issue of WorkCompRecap features the US Drug Enforcement Administration (DEA)’s announcement that it has recently eased some of the regulatory requirements imposed by the Controlled Substances Act (CSA) for those who are conducting FDA-approved clinical trials on cannabidiol (CBD), an extract of the marijuana plant.

Since CBD contains less than 1% THC and has shown some potential medicinal value, there is great interest in studying it for medical applications. The DEA noted that its modifications will streamline research processes regarding CBD’s possible medicinal value and help foster ongoing scientific studies by effectively removing an extra step for researchers who expanded the scope of their previously approved studies and needed more CBD.

Find out more by clicking here!

  • RSS
  • Twitter
  • LinkedIn